Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
13 janv. 2022 08h45 HE
|
Biofrontera Inc.
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...
Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe Acne
13 déc. 2021 09h09 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
06 déc. 2021 09h00 HE
|
Biofrontera Inc.
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Announces Closing of $15 Million Private Placement
01 déc. 2021 19h05 HE
|
Biofrontera Inc.
WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Kicks Off US Clinical Study Program for Ameluz®
16 nov. 2021 09h03 HE
|
Biofrontera Inc.
WOBURN, MA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced...
Biofrontera reports financial results for the six months ended June 30, 2021
19 août 2021 11h47 HE
|
Biofrontera AG
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
23 juil. 2021 04h15 HE
|
Biofrontera AG
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für...
Biofrontera provides update on clinical developments
22 juin 2021 09h00 HE
|
Biofrontera AG
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
Biofrontera reports preliminary revenue for the month of May 2021
07 juin 2021 10h01 HE
|
Biofrontera AG
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Biofrontera reports preliminary revenue for the month of April 2021
06 mai 2021 07h23 HE
|
Biofrontera AG
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...